We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ACAD market cap is 2.73B. The company's latest EPS is USD -0.3683 and P/E is -44.42.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 165.24M | 211.7M | 231.04M | 205.83M | 241.96M |
| Operating Income | 3.04M | -57.78M | 34.94M | 15.21M | 30.44M |
| Net Income | 1.11M | -65.18M | 45.8M | 16.56M | 33.39M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 339.08M | 441.76M | 484.15M | 517.24M | 726.44M |
| Operating Income | -246.55M | -286.59M | -170.44M | -223.6M | -73.38M |
| Net Income | -235.26M | -281.58M | -167.87M | -215.98M | -61.29M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 642.77M | 632.54M | 748.96M | 855.1M | 914.1M |
| Total Liabilities | 246.98M | 270.37M | 317.2M | 391.06M | 397.4M |
| Total Equity | 395.79M | 362.17M | 431.76M | 464.04M | 516.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 783.18M | 782.62M | 700.12M | 587.81M | 748.96M |
| Total Liabilities | 84.05M | 155.61M | 159.23M | 187.4M | 317.2M |
| Total Equity | 699.14M | 627.01M | 540.89M | 400.41M | 431.76M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -9.73M | -68.69M | 16.7M | 29.08M | 54.09M |
| Investing | -1.77M | 32.35M | 32M | -14.04M | -70.23M |
| Financing | 6.94M | 19.7M | 25.13M | 1.04M | 4.61M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -151.13M | -136.17M | -125.66M | -114.04M | 16.7M |
| Investing | -165.84M | 192.51M | -71.1M | 73.24M | 32M |
| Financing | 371.85M | 81M | 18.16M | 8.2M | 25.13M |
| Market Cap | 2.73B |
| Price to Earnings Ratio | -44.42 |
| Price to Sales Ratio | 3.75 |
| Price to Cash Ratio | 14.43 |
| Price to Book Ratio | 6.3 |
| Dividend Yield | - |
| Shares Outstanding | 166.39M |
| Average Volume (1 week) | 1.48M |
| Average Volume (1 Month) | 1.45M |
| 52 Week Change | -26.36% |
| 52 Week High | 32.59 |
| 52 Week Low | 14.15 |
| Spread (Intraday) | 0.59 (3.49%) |
| Company Name | Acadia Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.acadia-pharm.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
